goserelin acetate

P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Sep 2026

She underwent neoadjuvant chemotherapy (doxorubicin/cyclophosphamide followed by paclitaxel), followed by a left radical mastectomy with axillary dissection. Hormonal therapy (goserelin and exemestane) and adjuvant radiotherapy were initiated...Hormone receptor status, tumor biology, and extent of disease all influence treatment decisions. This rare clinical scenario highlights the need for further research and specific management guidelines.

This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with HR-positive/HER2-negative EBC. An ongoing positive trend for improved OS in favor of ribociclib + NSAI was observed.

P1, N=66, Recruiting, EMD Serono Research & Development Institute, Inc. | N=36 --> 66

P2, N=75, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

P2, N=60, Not yet recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital

P3, N=1538, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed

P3, N=239, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2029 --> Sep 2025

P4, N=10, Completed, University of Colorado, Denver | Recruiting --> Completed | N=228 --> 10 | Trial completion date: Mar 2028 --> Jul 2025 | Trial primary completion date: Mar 2028 --> Jul 2025

P2, N=87, Recruiting, Atossa Therapeutics, Inc. | N=214 --> 87 | Trial completion date: Sep 2026 --> Apr 2027 | Trial primary completion date: Feb 2026 --> Nov 2026

Oesophageal metastasis of prostate cancer is extremely rare and typically indicates advanced disease with a poor prognosis. The clinical manifestations are nonspecific and often lead to misdiagnosis. A definitive diagnosis relies on histopathology and immunohistochemical markers, such as PSA and P504S. Clinicians should maintain a high index of suspicion for metastatic prostate cancer in cases of unexplained oesophageal lesions. We hope that this case will increase clinicians' awareness of metastatic oesophageal cancer.

This study underscores NQO1, CLPP, HMGCR, and SORD as potential therapeutic targets for BPH, offers mechanistic insights into the efficacy of bicalutamide and zoladex and provides novel insights into potential therapeutic strategies for patients with BPH. However, attention should still be paid to the control of side effects in their clinical application.